Featured Speakers

• 

  Professor Paul Fitzgerald

  Director, School of Medicine and Psychology
  The Australian National University, Canberra.

  Advancing Non-invasive Brain Stimulation for Depression with Personalised Treatment Approaches

  Professor Paul Fitzgerald is the Head of the School of Medicine and Psychology at the Australian National University. He is an academic psychiatrist with a MBBS degree, Masters of Psychological Medicine and research PhD. He has conducted an extensive range of experimental studies and clinical trials, focused on the development of novel treatments options for patients with mental health conditions such as depression, schizophrenia, obsessive compulsive disorder, PTSD, autism and Alzheimer’s disease. He has a special interest in repetitive transcranial magnetic stimulation (rTMS) and other novel treatments using forms of non-invasive brain stimulation. He has had continual national grant support for over 20 years. He has published several books, approximately 600 journal articles and been cited over 30,000 times as well as established multiple clinical rTMS services and founded several device and clinical service companies.

• 

  Professor Jennifer Rodger

  Head of Brain Plasticity Research
  Perron Institute, Western Australia.

  Translational rTMS research: finding more questions than answers.

  Jenny Rodger is a Professor at the University of Western Australia and Head of Brain Plasticity at the Perron Institute for Neurological and Translational Science in Perth. Her research investigates mechanisms of brain plasticity and repair, with a focus on preclinical studies of neuromodulation in injured and abnormal brain circuits, and brain-based treatments for neuropsychiatric disorders. Her lab has pioneered repetitive transcranial magnetic stimulation (rTMS) studies in preclinical models and engineered miniaturised rTMS devices to fill critical translational gaps. Her research findings have been included in clinical handbooks and guidelines and have triggered a re-evaluation of the way rTMS is used in the clinic, leading to clinical trials in spinal cord injury, multiple sclerosis and depression.